HCWB is trading approximately 9.9% down at $2.36 after announcing the termination of its exclusive worldwide license agreement with Wugen.
- By ending the agreement, HCW Biologics regained full ex vivo rights to immunotherapeutic molecules HCW9201 and HCW9206, allowing the company to seek new strategic partnerships.
- The market pullback follows a sharp rally last week and recent sessions marked by significant double-digit percentage swings in the stock price.